Evogene (EVGN) Q1 2026 earnings review
The Painful Cost of a Strategic Pivot
Evogene's Q1 2026 results expose the harsh financial reality of its transition into a pure-play AI small molecule discovery company. Revenue collapsed 86% YoY to a negligible $0.3M as legacy seed sales vanished. While operating loss was relatively stable at $3.2M thanks to aggressive prior-year cost cuts, net loss reversed and ballooned to $5.9M due to a highly dilutive warrant transaction. Management expects $4.25M in upcoming cash distributions from divested subsidiaries to bridge the gap, but with the cancellation of a major Bayer collaboration and Casterra revenues pushed out to 2027, Evogene is surviving on fumes while waiting for its early-stage pharma partnerships to mature.
🐂 Bull Case
The company added three new collaborations in Q1 (Systasy, QUT, Unravel), proving early interest in the ChemPass AI platform within the biotech space.
Evogene expects to receive $4.25M in cash dividends from Lavie Bio and Biomica in Q2 2026, providing critical runway without further equity dilution.
🐻 Bear Case
The termination of the Bayer herbicide project removes a critical validation partner and casts doubt on the predictive accuracy of the platform in agriculture.
Raising $3.4M in February required issuing over 5 million new warrants at $1.25, triggering a massive $3.8M financing expense that crushed the bottom line.
⚖️ Verdict: 🔴
Bearish. The technology narrative is compelling, but the fundamental data shows an 86% revenue drop, a major partnership failure, and highly destructive financing maneuvers. The company is in a race against time.
Key Themes
Bayer Collaboration Fails, Contradicting Narrative
Management stated in the release that they are 'expanding our product pipeline in pharma and agriculture.' However, the data contradicts this optimism: AgPlenus and Bayer discontinued their herbicide development project because the target protein did not meet required product criteria. This is a Reversing trend for the ag-chem vertical, as losing a tier-1 partner highlights the high failure rate inherent in the industry, even with AI tools.
Punishing Cost of Capital
To secure a meager $3.4M in gross cash in February 2026, Evogene induced warrant exercises by issuing 5.07M new warrants at $1.25. The accounting for this maneuver resulted in a $3.8M financing expense. This highlights a severe lack of leverage in capital markets and aggressively dilutes existing shareholders just to keep the lights on.
Casterra Commercialization Pushed to 2027
The Casterra subsidiary, which drove the bulk of H1 2025 revenue, has Decelerated to a near halt. Operations have been slashed and refocused exclusively on Brazil. Management noted that current field trials will form the basis for seed sales in the 2027 growing season, effectively abandoning meaningful revenue generation from this unit for the next 12-18 months.
Pharma Partnering Momentum Accelerating
The pivot to pharma is showing early operational traction. Evogene signed three new collaborations in Q1 (Systasy Biosciences, Queensland University of Technology, and Unravel Biosciences), bringing its public pharma roster to four. These deals target complex areas like demyelinating disorders and chemotherapy resistance, serving as vital proof-of-concept for the ChemPass AI engine.
Deepening Google Cloud Integration
Evogene initiated a second phase of its collaboration with Google Cloud in February 2026. The goal is to integrate advanced AI agents using Vertex AI into ChemPass AI to automate complex scientific workflows. This is a critical technological moat designed to move the platform from simple generation to 'autonomous discovery.'
Subsidiary Wind-Downs Provide Non-Dilutive Capital
The decision to strip down non-core assets is finally yielding cash. Lavie Bio and Biomica received court approvals to distribute $4.25M and $2.7M in dividends, respectively. Evogene's combined cut will be approximately $4.25M, providing crucial liquidity expected to land in Q2 2026.
Geopolitical Environment Remains Unstable
While not directly impacting the Q1 numbers, management explicitly reiterated the ongoing risks associated with the aftermath of the war in Israel and surrounding regional destabilization. As an Israel-based tech company heavily reliant on local R&D talent, the macro environment remains a persistent operational overhang.
Other KPIs
Stable sequentially, but Decelerating significantly YoY (down from $2.47M in 25Q1). This reflects the aggressive cost-cutting measures implemented throughout 2025, which saw AgPlenus and Evogene core staff reduced by 30-40%. The company appears to have found its new, lower baseline for development costs.
Consolidated cash, equivalents, and short-term deposits remain relatively healthy compared to the $2.8M quarterly cash burn. However, this balance was only maintained through the highly dilutive $3.4M warrant inducement.
Guidance
Accelerating liquidity. Management expects to complete the distribution process for Lavie Bio (~$2.9M to Evogene) and Biomica (~$1.35M to Evogene) in the second quarter. This is a critical non-dilutive injection that offsets the operating burn for more than a full quarter.
Decelerating. Prior narratives hoped for continuous Casterra expansion in Africa and Brazil. The new guidance explicitly pushes meaningful seed sales out to 2027, confirming that the legacy ag-business will not rescue the income statement in 2026.
Key Questions
Bayer Project Autopsy
The Bayer herbicide project was terminated because the APTH1 target protein failed to meet criteria. Was this a failure of the ChemPass AI predictive model, or a failure in subsequent biological validation? How does this impact confidence in your internal fungicide programs?
Pharma Deal Economics
You announced three new pharma collaborations this quarter. Can you provide clarity on the economic structure of these deals? Do they include upfront cash, or are they purely milestone and royalty-based?
Future Financing Strategy
The February warrant inducement triggered a massive $3.8 million financing expense to raise $3.4 million. Given the incoming subsidiary dividends, can management commit to avoiding similar highly dilutive and optically toxic financing structures for the remainder of the year?